Drogenscreening im Untersuchungsmaterial (verschieden)
Klinische Indikation
BeurteilungBerücksichtigte Substanzen (Stand: Nov.2023) Amphetamine: BDB, Butylon, D-/L-Amphetamin, D-/L-Methamphetamin, MBDB, MDA, MDEA, MDMA, MDPV, Mephedron, Methylon, 4-Methylethcathinon, Pentedron, PMMA, alpha-PVP Benzodiazepine: Alprazolam, Bromazepam, Diazepam, Flunitrazepam, Flurazepam, Desalkylflurazepam, Lorazepam, Midazolam, Nordiazepam, Oxazepam, Temazepam, Phenazepam Cocain-Metabolit: Benzoylecgonin, Kokain Opiate: 6-Acetylcodein, 6-Acetylmorphin, Codein, Dihydrocodein, Morphin, Norcodein, Noscapin Opioide: Dextromethorphan, Loperamid, Mitragynin,Fentanyl, Hydromorphon, Naloxon, Noroxycodon, Nortilidin, O-Desmethyltramadol, Oxycodon, Tilidin, Tramadol Cannabinoide: THC, CBD, HHC (Hexahydrocannabinol) Sonstige: Bupropion, Citalopram, Diphenhydramin, Doxepin, Gabapentin, Ketamin, Lidocain, Methylphenidat, Ritalinsäure, Mirtazapin, Pregabalin, Quetiapin, Venlafaxin, Zaleplon, Zolpidem, Zopiclon Referenzbereiche / Entscheidungsgrenze
Sonstiges
|
Stand: 29.01.2024 |